Rothfuss Cristin 4

What Happened Cristin Rothfuss, Executive Vice President and General Counsel of Sarepta Therapeutics (SRPT), had 830 shares withheld by the company on March 9, 2026 to satisfy tax withholding obligations tied to vested restricted stock units (RSUs). The two withholdings were 484 shares and 346 shares, each priced at $16.95, for total value withheld of $8,204 and $5,865 respectively (combined ≈ $14,069). These were tax-withholding dispositions (code F), not open-market sales.

Key Details

• Transaction date: 2026-03-09; Form 4 filed: 2026-03-11 (appears timely).
• Prices: 484 shares @ $16.95 and 346 shares @ $16.95.
• Total withheld: 830 shares for about $14,069.
• Transaction code: F (shares withheld to satisfy tax withholding).
• Footnotes: Withholding relates to vesting of RSUs granted March 7, 2022 (F1) and March 6, 2023 (F2).
• Shares owned after transaction: Not reported in the provided filing.

Context Share withholding to cover tax on vested RSUs is a common, administrative disposition and is different from an open-market sale. It typically does not indicate a discretionary sell decision by the insider. The filing shows the company retained shares to meet tax obligations arising from prior RSU grants.